作者: Lawrence H Einhorn , PJ Loehrer , SD Williams , S Meyers , T Gabrys
DOI: 10.1200/JCO.1986.4.7.1037
关键词:
摘要: In this phase III randomized study, 124 evaluable patients with unresectable non-small-cell lung cancer (NSCLC) were to vindesine v cisplatin (120 mg/m2) plus (60 mitomycin C. The objective response rate for and was 27% 20% cisplatin, vindesine, C, 14% alone (P = .25 vindesine). percentage of having stable disease (no progression a minimum 3 months) (cisplatin vindesine), (cisplatin, C), 26% (vindesine alone), respectively. median survival time 18 weeks, compared 26 weeks 17 Overall not statistically different .65). There no evidence improved duration remission or responders the ...